Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. PPTDF.PINK

PeptiDream Inc (PPTDF PINK) stock market data APIs

$14.3 0(0%) as of July 25, 2024
Price chart is built with Anychart

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. The company, through its subsidiary PDRadiopharma Inc., is involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. It has a collaboration with Novartis Pharma AG. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.

PeptiDream Inc Financial Data Overview

14.3
14.3
-
14.3
14.3
7.4-14.3
2 221 M
119.1667
130 M
27 974 M
-0.0438
0.582
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PPTDF',
Type: 'Common Stock',
Name: 'PeptiDream Inc',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG006Z5JGB8',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

PeptiDream Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 27 974 M
  • EBITDA 8 436 M
  • Earnings Per Share 0.12
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get PeptiDream Inc Earnings via APIs

  • Latest Release 2024-05-14
  • EPS/Forecast NaN

Get PeptiDream Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get PeptiDream Inc latest news via APIs

PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates

KAWASAKI, Japan, September 20, 2023--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4...

Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders

TOKYO & KAWASAKI, Japan, July 25, 2023--(BUSINESS WIRE)--Astellas Pharma Inc. (TOKYO: 4503, President and CEO: Naoki Okamura, "Astellas") and PeptiDream Inc. (TOKYO: 4587, President and CEO: Patrick C...
Do you have any questions?
support@eodhistoricaldata.com